180 related items for PubMed ID: 35290211
1. Treatment of congenital adrenal hyperplasia in children aged 0-3 years: a retrospective multicenter analysis of salt supplementation, glucocorticoid and mineralocorticoid medication, growth and blood pressure.
Neumann U, van der Linde A, Krone RE, Krone NP, Güven A, Güran T, Elsedfy H, Poyrazoglu S, Darendeliler F, Bachega TASS, Balsamo A, Hannema SE, Birkebaek N, Vieites A, Thankamony A, Cools M, Milenkovic T, Bonfig W, Costa EC, Atapattu N, de Vries L, Guaragna-Filho G, Korbonits M, Mohnike K, Bryce J, Ahmed SF, Voet B, Blankenstein O, Claahsen-van der Grinten HL.
Eur J Endocrinol; 2022 Apr 11; 186(5):587-596. PubMed ID: 35290211
[Abstract] [Full Text] [Related]
2. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM, Simm D, Beier C, Dörr HG.
Pediatrics; 2006 Jan 11; 117(1):e98-105. PubMed ID: 16396852
[Abstract] [Full Text] [Related]
3. Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose.
Bonfig W, Roehl F, Riedl S, Brämswig J, Richter-Unruh A, Fricke-Otto S, Hübner A, Bettendorf M, Schönau E, Dörr H, Holl RW, Mohnike K.
Horm Res Paediatr; 2018 Jan 11; 89(1):7-12. PubMed ID: 29073619
[Abstract] [Full Text] [Related]
4. Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature.
Ahmed SEAM, Soliman AT, Ramadan MA, Elawwa A, Abugabal AMS, Emam MHA, De Sanctis V.
Acta Biomed; 2019 Sep 06; 90(3):360-369. PubMed ID: 31580328
[Abstract] [Full Text] [Related]
5. Gender dichotomy in long term growth trajectories of children with 21-hydroxylase deficiency congenital adrenal hyperplasia.
Patel L, Chandrashekhar SR, Gemmell I, O'Shea E, Jones J, Banerjee I, Amin R, Clayton P.
Horm Res Paediatr; 2011 Sep 06; 75(3):206-12. PubMed ID: 20962509
[Abstract] [Full Text] [Related]
6. Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy.
Sellick J, Aldridge S, Thomas M, Cheetham T.
J Pediatr Endocrinol Metab; 2018 Sep 25; 31(9):1019-1022. PubMed ID: 30173205
[Abstract] [Full Text] [Related]
7. Synthetic glucocorticoids instead of hydrocortisone do not increase mineralocorticoid needs in adult patients with salt wasting congenital adrenal hyperplasia.
Auer MK, Paizoni L, Nowotny H, Lottspeich C, Tschaidse L, Schmidt H, Bidlingmaier M, Reisch N.
J Steroid Biochem Mol Biol; 2023 Jun 25; 230():106271. PubMed ID: 36764494
[Abstract] [Full Text] [Related]
8. Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age.
Bonfig W, Schwarz HP.
Clin Endocrinol (Oxf); 2014 Dec 25; 81(6):871-5. PubMed ID: 24818525
[Abstract] [Full Text] [Related]
9. Growth and Metabolic Syndrome (MetS) criteria in young children with classic Congenital Adrenal Hyperplasia (CAH) treated with corticosteroids (CS).
Abdel Meguid SE, Soliman AT, De Sanctis V, Abougabal AMS, Ramadan MAEF, Hassan M, Hamed N, Ahmed S.
Acta Biomed; 2022 Oct 26; 93(5):e2022304. PubMed ID: 36300207
[Abstract] [Full Text] [Related]
10. International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry.
Bacila I, Freeman N, Daniel E, Sandrk M, Bryce J, Ali SR, Yavas Abali Z, Atapattu N, Bachega TA, Balsamo A, Birkebæk N, Blankenstein O, Bonfig W, Cools M, Costa EC, Darendeliler F, Einaudi S, Elsedfy HH, Finken M, Gevers E, Claahsen-van der Grinten HL, Guran T, Güven A, Hannema SE, Higham CE, Iotova V, van der Kamp HJ, Korbonits M, Krone RE, Lichiardopol C, Luczay A, Mendonca BB, Milenkovic T, Miranda MC, Mohnike K, Neumann U, Ortolano R, Poyrazoglu S, Thankamony A, Tomlinson JW, Vieites A, de Vries L, Ahmed SF, Ross RJ, Krone NP.
Eur J Endocrinol; 2021 Apr 26; 184(4):553-563. PubMed ID: 33460392
[Abstract] [Full Text] [Related]
11. Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency.
Bonfig W, Roehl FW, Riedl S, Dörr HG, Bettendorf M, Brämswig J, Schönau E, Riepe F, Hauffa B, Holl RW, Mohnike K, AQUAPE CAH Study Group.
Am J Hypertens; 2016 Feb 26; 29(2):266-72. PubMed ID: 26071487
[Abstract] [Full Text] [Related]
12. Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report.
Roche EF, Charmandari E, Dattani MT, Hindmarsh PC.
Clin Endocrinol (Oxf); 2003 May 26; 58(5):589-96. PubMed ID: 12699440
[Abstract] [Full Text] [Related]
13. Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Irony I, Cutler GB.
Clin Endocrinol (Oxf); 1999 Sep 26; 51(3):285-91. PubMed ID: 10469007
[Abstract] [Full Text] [Related]
14. The urinary steroidome of treated children with classic 21-hydroxylase deficiency.
Kamrath C, Wettstaedt L, Boettcher C, Hartmann MF, Wudy SA.
J Steroid Biochem Mol Biol; 2017 Jan 26; 165(Pt B):396-406. PubMed ID: 27544322
[Abstract] [Full Text] [Related]
15. Hypertension in children with congenital adrenal hyperplasia.
Maccabee-Ryaboy N, Thomas W, Kyllo J, Lteif A, Petryk A, Gonzalez-Bolanos MT, Hindmarsh PC, Sarafoglou K.
Clin Endocrinol (Oxf); 2016 Oct 26; 85(4):528-34. PubMed ID: 27105393
[Abstract] [Full Text] [Related]
16. Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for age dependent treatment in childhood and puberty.
Pijnenburg-Kleizen KJ, Thomas CMG, Otten BJ, Roeleveld N, Claahsen-van der Grinten HL.
J Pediatr Endocrinol Metab; 2019 Oct 25; 32(10):1055-1063. PubMed ID: 31573958
[Abstract] [Full Text] [Related]
17. Reinstitution of mineralocorticoid therapy in congenital adrenal hyperplasia. Effects on control and growth.
Jansen M, Wit JM, van den Brande JL.
Acta Paediatr Scand; 1981 Mar 25; 70(2):229-33. PubMed ID: 7015786
[Abstract] [Full Text] [Related]
18. Do All Patients with Congenital Adrenal Hyperplasia Need to Be on Hydrocortisone Three Times a Day in Order to Have Normal Growth?
Logan LA, Nebesio TD, Eckert GJ, Eugster EA.
Horm Res Paediatr; 2022 Mar 25; 95(5):461-464. PubMed ID: 35649383
[Abstract] [Full Text] [Related]
19. Molecular testing in congenital adrenal hyperplasia due to 21α-hydroxylase deficiency in the era of newborn screening.
Sarafoglou K, Lorentz CP, Otten N, Oetting WS, Grebe SK.
Clin Genet; 2012 Jul 25; 82(1):64-70. PubMed ID: 21534945
[Abstract] [Full Text] [Related]
20. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience.
Hoepffner W, Kaufhold A, Willgerodt H, Keller E.
Horm Res; 2008 Jul 25; 70(1):42-50. PubMed ID: 18493149
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
